This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
healthcare: Archive
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
by Urmimala Biswas
CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
healthcare medical retail smart-health
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
healthcare medical medical-devices pharmaceuticals
These Top 4 Women-Run Company Stocks Are Quietly Beating the Market
by Shrabana Mukherjee
These women-run company stocks offer high growth and stability.
healthcare internet medical medical-devices tech-stocks thematic
CVS vs. Amazon: Healthcare Battle Continues- Which Stock to Buy Now?
by Urmimala Biswas
CVS surges with a 56% YTD return and an integrated care model, as AMZN bets on tech and logistics to reshape healthcare.
healthcare medical retail smart-health
BTSG vs. OPCH: Which Home Infusion Stock is a Better Buy Now?
by Urmimala Biswas
BTSG surges with 33% infusion growth and stronger EPS gains, making it a more compelling pick than OPCH right now.
earnings-estimates-revisions earnings-outlook earnings-report healthcare hospitals medical smart-health
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
by Urmimala Biswas
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
artificial-intelligence biotechnology cancer earnings-outlook healthcare medical
CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?
by Urmimala Biswas
CVS surges 53.7% YTD as regulatory relief, strong execution and Medicare Advantage momentum fuel investor confidence.
earnings-outlook healthcare medical retail
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
biotechs cancer crispr gene-editing gene-therapy healthcare medical
BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?
by Urmimala Biswas
BTSG stock hits an all-time high with a 120% gain as soaring quality ratings and strong Q1 results fuel investor confidence.
earnings-outlook earnings-report healthcare medical medical-devices
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
by Urmimala Biswas
Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?
artificial-intelligence earnings-report healthcare medical medical-devices smart-health